Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 23, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Annual Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of GBP13.17 per share, which was the price at which dividends were re-invested on January 10, 2008.
Material Changes
The document reports an increase in share interests for specific individuals following the re-investment of dividends paid on January 10, 2008. The specific increases are as follows:
- Dr M M Slaoui: 213 shares
- Mr R M Bondy: 279 shares
- Mr M Dunoyer: 104 shares
- Mr D Learmouth: 19 shares
- Dr D Pulman: 158 shares
- Mr A P Witty: 97 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is strictly a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Dividend re-investment occurred on January 10, 2008, at a price of GBP13.17 per share.
- Transactions were notified to the Company on January 23, 2008.
- The filing confirms compliance with UK Disclosure and Transparency Rules regarding director shareholdings.
- No operational or financial performance data is included in this specific report.